Document Detail

Preoperative embolization of intracranial arteriovenous malformations with Onyx.
MedLine Citation:
PMID:  17762736     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Preoperative embolization in accordance with multimodal therapies for cerebral arteriovenous malformations (AVMs) is generally the first step in treatment and may result in complete obliteration. The Onyx liquid embolic system (Micro Therapeutics, Inc., Irvine, CA) may offer advantages for intranidal targeted embolization and microsurgical resection. We present our experience in the combined treatment of intracranial AVMs using Onyx embolization and neurosurgical resection. METHODS: We treated a total of 47 patients for compact intracranial AVMs that were located in the frontal or frontoparietal area (16 patients); temporal, temporoparietal, or temporo-occipital regions (12 patients); parietal or parieto-occipital areas (8 patients); occipital regions (8 patients); had basal ganglia involvement (2 patients); and was cerebellar (1 patient). The Spetzler-Martin grading scale values were as follows: 25 patients were Grades I or II, 10 patients were Grade III, and 12 patients were Grades IV or V. Twenty-three AVMs were located in eloquent brain regions. RESULTS: After we performed final embolizations, the mean nidus reduction was 84%. Seven patients had new, nondisabling neurological deficits, and four patients had new, disabling neurological deficits after embolization. Periprocedurally, five vessel perforations and four stuck microcatheters were encountered without clinical deficits. In two patients, delayed hemorrhage after embolization occurred with good clinical outcome. We completely resected 46 AVMs; in one patient, we detected an AVM on postoperative angiography. The mean operative time was 4.7 hours, and the mean blood loss was 455 mL. Clinical status worsened postoperatively in 14 patients. Angiographic and clinical follow-up examinations were available for 42 patients (89%); the average follow-up period was 13 months. We found no relapse of arteriovenous shunt. Fourteen patients improved clinically after discharge. Of the 42 patients followed up, 23 individuals had no neurological deficit, 16 had a nondisabling deficit, and three had a disabling deficit. CONCLUSION: Preoperative use of the Onyx liquid embolic system in cerebral AVM treatment allows profound occlusion by targeted embolization and provides a basis for safe neurosurgical resection.
Werner Weber; Bernhard Kis; Ralf Siekmann; Paul Jans; Rudolf Laumer; Dietmar Kühne
Related Documents :
21340176 - Distinctive profile of the 17-hydroxylase and 17,20-lyase activities revealed by urinar...
2880316 - Prevention of symptomatic vasospasm after sah by constant venous infusion of nimodipine.
25255726 - Carotid duplex criteria for patients with contralateral occlusion.
25182196 - Quantitative measurement of brain iron deposition in patients with haemodialysis using ...
15032026 - Bullous pemphigoid: course of the disease. a study of 25 patients.
3132806 - Hodgkin's disease of the oesophagus.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Neurosurgery     Volume:  61     ISSN:  1524-4040     ISO Abbreviation:  Neurosurgery     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-08-31     Completed Date:  2007-09-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7802914     Medline TA:  Neurosurgery     Country:  United States    
Other Details:
Languages:  eng     Pagination:  244-52; discussion 252-4     Citation Subset:  IM    
Department of Radiology and Neuroradiology, Alfried Krupp Hospital, Essen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cerebral Angiography
Combined Modality Therapy
Dimethyl Sulfoxide*
Embolization, Therapeutic / methods*
Follow-Up Studies
Intracranial Arteriovenous Malformations / surgery*,  therapy*
Middle Aged
Neurosurgical Procedures*
Postoperative Complications / radiography
Preoperative Care
Treatment Outcome
Reg. No./Substance:
0/Onyx copolymer; 0/Polyvinyls; 67-68-5/Dimethyl Sulfoxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A 7-year experience with balloon-mounted coronary stents for the treatment of symptomatic vertebroba...
Next Document:  Early plasma complement C3a levels correlate with functional outcome after aneurysmal subarachnoid h...